摘要
Background:The Ad26.COV2.S vaccine,which was approved as a single-shot immunization regimen,has been shown to be effective against severe coronavirus disease 2019.However,this vaccine induces lower severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)spike protein(S)-specific antibody levels than those induced by messenger RNA(mRNA)-based vaccines.The immunogenicity and reactogenicity of a homologous or heterologous booster in persons who have received an Ad26.COV2.S priming dose are unclear.
出处
《四川生理科学杂志》
2021年第11期1861-1861,共1页
Sichuan Journal of Physiological Sciences
